You don’t expect a routine checkup to change your life. But for too many Black men, that’s exactly how it happens, one conversation, one test result, and suddenly everything shifts. You have prostate cancer. For many Black men and their families, that moment carries more weight. Not just because of the diagnosis, but because prostate […]

This Managing Survivorship session was titled Treatment Options Update for Patients Newly Diagnosed or with Recurrent Prostate Cancer. The speakers included PHEN Director of Clinical Trials and Patient Education, Dr. Keith Crawford, and PHEN Senior Scientific Research Analyst, Dr. David Vasir. The speakers presented details regarding NCCN prostate cancer screening updates, treatment options, and clinical […]

If you’re a prostate cancer patient, you’ve likely heard how helpful fitness is for your health. However, did you know physical fitness can help you manage the side effects of treatment? How about the best type of exercise for prostate cancer survivors? Keep reading to find out. In a Managing Prostate Cancer Survivorship webinar, PHEN’s […]

As part of the Jackson, MS Disparity Rally, Dr. Timothy Quinn, the Medical Director of Quinn Healthcare, explains the importance of early prostate cancer detection to save lives. Dr. Quinn advises men to visit PHENPath.com for information on the latest prostate cancer treatments. Watch Video #ProstateCancer #CancerTreatments #ProstateCancerAwareness #CancerScreening #ProstateCancerDetection #Jackson #Mississippi #ProstateCancerDisparity #DisparityRally #PHEN

PHEN’s Clinical Trials Rally’s approach of educating Black prostate cancer patients about clinical trials, as well as strategic partnerships with pharmaceutical companies to amplify this message, is contributing to greater diversity among clinical trial participants. In addition to Pfizer’s TALAPRO-2 clinical trial featured in FDA approved post, PHEN also supported its TALAPRO-3 trial. Pfizer reported that they […]

The U.S. Food and Drug Administration (FDA) recently approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). TALZENNA is the first and only PARP inhibitor approved for use with an existing standard of care (XTANDI) for adult patients with this condition. The FDA’s approval of the combination […]

PHEN is a partner organization of the Amgen Clinical Pathways initiative, PHENPath.com helps empower prostate cancer patients through its first digital treatment pathway tool of its kind. We encourage you to read the article by clicking the button link below